Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

Mauricio de Carvalho; Ita Pfeferman Heilberg

doi:10.1590/2175-8239-JBN-2023-0146en

Sodium-glucose cotranspor ter 2 (SGLT2) inhibitors in nephrolithiasis: should we "gliflozin" patients with kidney stone disease?

J Bras Nefrol. 2024 Jul-Sep;46(3):e20230146. doi: 10.1590/2175-8239-JBN-2023-0146en.

[Article in English, Portuguese]

Authors

Mauricio de Carvalho^{1

2}, Ita Pfeferman Heilberg³

Affiliations

¹ Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, Paraná, Brazil.
² Universidade Federal do Paraná, Departamento de Clínica Médica, Curitiba, Paraná, Brazil.
³ Universidade Federal de São Paulo, Escola Paulista de Medicina, São Paulo, São Paulo, Brazil.

PMID: 38498673
DOI: 10.1590/2175-8239-JBN-2023-0146en

Abstract

The prevalence of nephrolithiasis is increasing worldwide. Despite advances in understanding the pathogenesis of lithiasis, few studies have demonstrated that specific clinical interventions reduce the recurrence of nephrolithiasis. The aim of this review is to analyze the current data and potential effects of iSGLT2 in lithogenesis and try to answer the question: Should we also "gliflozin" our patients with kidney stone disease?

Publication types

Review

MeSH terms

Humans
Kidney Calculi* / complications
Nephrolithiasis* / drug therapy
Nephrolithiasis* / epidemiology
Sodium
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use

Substances

Sodium
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Transporter 2